NASDAQ · PVLA
Healthcare · Biotechnology
$146.15
Down-$5.43 (-3.58%)
Updated Nov 1, 2026, 11:30 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PVLA
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
PVLA closed at $146.15 after 20 trading sessions, up 10.59% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $149.49 | $150.90 | $144.095 | $146.15 | 293.06K |
| Oct 29, 2026 | $149.65 | $156.82 | $146.4701 | $151.58 | 342.96K |
| Oct 28, 2026 | $134.15 | $147.91 | $132.94 | $147.47 | 368.24K |
| Oct 27, 2026 | $126.31 | $133.33 | $125.625 | $132.91 | 178.77K |
| Oct 26, 2026 | $126.52 | $127.20 | $123.83 | $126.23 | 110.52K |
| Oct 23, 2026 | $124.60 | $125.93 | $121.34 | $125.10 | 164.22K |
| Oct 22, 2026 | $125.09 | $127.91 | $123.475 | $126.39 | 104.72K |
| Oct 21, 2026 | $125.39 | $128.48 | $122.82 | $126.58 | 255.79K |
| Oct 20, 2026 | $123.30 | $131.03 | $122.54 | $123.92 | 267.71K |
| Oct 19, 2026 | $121.93 | $125.075 | $120.75 | $122.96 | 271.68K |
| Oct 16, 2026 | $127.27 | $127.27 | $118.225 | $120.30 | 182.22K |
| Oct 15, 2026 | $123.58 | $129.49 | $122.51 | $127.34 | 240.97K |
| Oct 14, 2026 | $125.53 | $128.29 | $120.27 | $122.58 | 384.51K |
| Oct 13, 2026 | $134.08 | $134.14 | $127.97 | $128.51 | 215.84K |
| Oct 12, 2026 | $137.27 | $138.48 | $131.78 | $134.38 | 213.79K |
| Oct 9, 2026 | $130.70 | $139.86 | $128.80 | $138.77 | 174.04K |
| Oct 8, 2026 | $129.90 | $131.95 | $124.49 | $131.34 | 209.33K |
| Oct 7, 2026 | $125.97 | $131.345 | $125.00 | $130.59 | 151.99K |
| Oct 6, 2026 | $133.75 | $133.85 | $124.97 | $128.00 | 309.99K |
| Oct 5, 2026 | $132.50 | $133.265 | $129.51 | $132.16 | 142.88K |
The latest Smart Investors Daily articles mentioning PVLA.
Company
Market Activity
Research & News
PVLA research
Company profile and research snapshot.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 28, 2026 | Chardan Capital | Buy | — |
| Oct 16, 2026 | William Blair | Outperform | — |
| Oct 12, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 21, 2026 | Chardan Capital | Buy | — |
| May 21, 2026 | Stephens & Co. | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 25, 2026
Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer Matt Korenberg said during a Chardan investor session. Korenberg said the company has expanded from deve
Yahoo · Oct 24, 2026
Palvella Therapeutics (NasdaqGM:PVLA) reported positive Phase 3 SELVA trial results for QTORIN rapamycin in microcystic lymphatic malformations. The company has completed an FDA New Drug Application for QTORIN rapamycin following the SELVA efficacy and safety findings. Management also released new real-world analyses on the prevalence and burden of DSAP as groundwork for QTORIN pitavastatin development. The QTORIN rapamycin SELVA readout and NDA filing, plus fresh DSAP data, sit within a...
Benzinga · Oct 16, 2026
William Blair analyst Alethia Young initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Outperform rating.
Yahoo · Oct 15, 2026
Phase 3 SELVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and a Blinded Combined Score of Lesion Height, Vesicle Appearance, and Leaking/Bleeding Phase 2 TOIVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and Reductions in Lesion Bleeding in Previously Treated Children with Cutaneous Venous Malformations QTORIN™ Rapamycin Has the Potential to Become the First FDA-Approved Therapy for Both Microcystic Lymphatic Malformations and Cutaneous Venous
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PVLA.
